Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial

Avecho Biotechnology (ASX:AVE) has begun patient recruitment for the Phase III clinical trial of its anti-insomnia medication, the company said in a Tuesday filing with the Australian Securities Excha

MT NewswiresMar 26 06:37

Avecho to Push Forward With Phase III Trial of Anti-Insomnia Drug

Avecho Biotechnology (ASX:AVE) said the Australian Therapeutic Goods Administration (TGA) has "not recommended any changes" to the design and submission strategy of the firm's proposed Phase III clini

MT NewswiresMar 14 19:41

Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial

Avecho Biotechnology (ASX:AVE) secured ethics approval to advance its phase three insomnia trial, according to a filing with the Australian Securities Exchange on Thursday. The study aims to investiga

MT NewswiresMar 7 14:11

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Yahoo FinanceJan 13, 2023 07:04

Transdermal Drug Delivery Pipeline Report 2022 - ResearchAndMarkets.com

The "Transdermal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

BusinesswireSep 16, 2022 19:21